Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
USD/CAD Price Forecast: Remains in tight range near 1.4200, eyes on US NFP

USD/CAD Price Forecast: Remains in tight range near 1.4200, eyes on US NFP

FXStreetFXStreet2026/07/02 06:57
By:FXStreet

The USD/CAD pair trades flat around 1.4210 during the European trading session on Thursday. The Loonie pair has remained sideways for over a week, with investors seeking fresh cues regarding the United States (US) interest rate outlook. For the same, investors await the US Nonfarm Payrolls (NFP) data for June, which will be published at 12:30 GMT.

According to estimates, the US economy created 110K fresh jobs, lower than 172K in May. The Unemployment Rate is seen remaining steady at 4.3%. Average Hourly Earnings, a key measure of wage growth, is estimated to arrive at 3.5% Year-on-Year (YoY), higher from 3.4% in May, with monthly figures rising steadily by 0.3%.

Assuming that wage growth drives the US core inflation significantly, investors will pay close attention to the data to get cues regarding the price rise outlook.

On Wednesday, Federal Reserve (Fed) Chairman Kevin Warsh warned at the European Central Bank (ECB) Forum in Sintra that inflation remains “too high”, while stressing the need to bring price stability.

Meanwhile, lower oil prices due to progress in indirect talks between the US and Iran, held in Doha on Wednesday, have diminished the appeal of currencies from economies, such as Canada, which are net oil exporters.

Technical Analysis:

USD/CAD trades flat at around 1.4200, while holding a clear bullish bias as spot remains above the 20-day exponential moving average (EMA) at 1.4103.

The Relative Strength Index (RSI) at 77.7 signals overbought conditions that could temper immediate upside without yet undermining the broader constructive tone.

On the downside, initial support is located at the 20-day EMA near 1.4103, where buyers are likely to defend the prevailing uptrend on any pullback. Looking up, the pair could extend its advance towards the 1 April 2025 high at 1.4415 if it breaks the ongoing consolidation inside the 1.4169-1.4248 upwards.

(The technical analysis of this story was written with the help of an AI tool.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales